---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-23-000195"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:13:39.722941+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Zentalis Q3: azenosertib 37% ORR, $517M cash, NDA on track for 2026

## Summary
- Azenosertib monotherapy achieved 37% ORR and 6.5-month mPFS in heavily pretreated ovarian/uterine serous carcinoma.
- Cash, equivalents & marketable securities of $516.6M as of Sept 30, 2023; projected runway into 2026.
- First NDA for azenosertib targeted in 2026 for a gynecologic malignancy; numerous trials ongoing.
- Mark Lackner, Ph.D., to succeed co-founder Kevin Bunker, Ph.D., as Chief Scientific Officer at year-end.
- ZN-d5 development in AL amyloidosis discontinued to focus resources on azenosertib franchise.

## SEC filing metadata
- accession: 0001725160-23-000195
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000195/0001725160-23-000195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000195/zntl-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-23-000195
- JSON: https://secwatch.observer/filing/0001725160-23-000195.json
- Plain text: https://secwatch.observer/filing/0001725160-23-000195.txt

## Key facts
- Earnings Releases
  Zentalis Pharmaceuticals, Inc. reported financial results for quarter ended September 30, 2023.
  - Period: quarter ended September 30, 2023
  - Result: reported results
  source text: On November 6, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023 and commented on certain business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000195/0001725160-23-000195-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.